NC-TOPPS					
ADATC Episode Completion Interview					
(for patients with length of stay	greater than or equal to 5 days)				
**Use this form for backup only. Enter data into web-b	ased system. (https://nctopps.ncdmh.net/adatc.htm)				
Clinician First Initial & Last Nan	ne				
Please provide the following information about the individual:	7. Consumer Availability: (mark only one)				
Consumer Record Number (HEARTS #)	Consumer is Not Available/Already Been Discharged $\rightarrow$ (answer b) Consumer is Available $\rightarrow$ (skip to 8)				
	b. If 'Consumer is Not Available/Already Been Discharged', select the circumstance(s) as to why the consumer is not available:				
First three letters of consumer's last name: (If female, use consumer's maiden name)	(mark all that apply) Internal: External:				
	□ Treatment needs not met □ Legal □ Staff conflict □ Family				
First letter of consumer's first name:	Peer conflict     Medical				
Date of Birth	$\square$ Refused to take medication $\square$ Death -> STOP-end of interview				
	☐ Other (please list reason): ☐ Employment				
	School				
County of Residence:	Housing				
Gender Assigned at Birth:	Consumer refused				
Male Female	Other (please list reason):				
1. Please select the appropriate disability category for which the individual is receiving services and supports.	8. Please indicate the ICD-10-CM diagnosis code(s) for this				
(mark only one)  Substance Use Disorder	individual. (See Attachment I)				
Mental Health/Substance Use Disorder	9. Are you currently serving or have you ever served on active				
2. Please select the service(s) for which the individual	duty in the U.S. Armed Forces, National Guard or Military Reserves?				
<b>received during this treatment episode.</b> (mark only one)	$\square$ Yes $->$ (answer b)				
□ Inpatient Treatment	$\square \text{ No} \rightarrow (skip \text{ to } 10)$				
	b. If 'Yes', during your military service, did you experience any				
Both	traumatic event(s)?				
3. Type of Discharge: (mark only one)	□ Yes				
<ul> <li>AA - Against Medical Advice Discharge (AMA)</li> <li>BP - Behavior Problem Discharge</li> </ul>					
DC - Direct by Court Order	<b>10. Special Populations</b> (mark all that apply) □ Criminal Justice □ Mom with child (WBJ only)				
DI - Direct Discharge to Inpatient Commitment	HIV     Pregnant				
DM - Direct Discharge to Medical Visit	Homeless SSI/SSDI				
□ IL - Indirect Discharge from Leave	□ Injection Drug Use (IDU) □ TBI				
DA - Direct with Approval	Methadone     Mone of the above				
🗖 PR - Personal Reasons					
TD - Therapeutic Discharge	If 'Consumer is Not Available/Already Been Discharged', skip questions 11-19:				
TX - Permanent Transfer Out to Other State Facility	11. As you approach the end of this treatment episode, do you				
4. Date of Discharge	view your substance use history differently than reported at admission? Yes -> (answer 12)				
5. Discharge Tailored Plan:	□ No -> ( <i>skip to 13</i> )				
b. Discharge Tailored Plan Assigned Consumer Record Number					
6. Is the consent for a follow-up interview after discharge in the consumer's medical record?					

Confidentiality of SUD and MH consumer-identifying information is protected under Federal regulations 42 CFR Part 2 and the Health Insurance Portability and Accountability Act of 1996, P.L. 104-91 (HIPAA) or implementing regulations, 45 CFR Parts 160 and 164. Consumer-identifying information may be disclosed without the individual's consent to the Division of Mental Health, Developmental Disabilities, and Substance Use Services (DMH/DD/SUS) and to its authorized evaluation contractors under the audit or evaluation exception. Redisclosure of consumer-identifying information without the individual's consent is explicitly prohibited. Your questions may be directed to the NC-TOPPS ADATC Help Desk: nctoppsadatc@ncsu.edu. Sponsored by the NC MH/DD/SUS. Page 1

	NC-TOPPS					
ADATC Episode Completion Interview						
	-	-	ter than or equal to 5 days)			
	-		ystem. (https://nctopps.ncdmh.net/adatc.htm)			
12. If 'Yes', please indicate applicable), and Tertiary (i entering a "1" for Primary,	f applicable) substance	problems by	17. Did this consumer receive or was expected to receive naltrexone (such as Revia, Vivitrol, etc.) treatment?			
Alcohol	Marijuana/ Hashish	Cocaine/Crack	<ul> <li>☐ Yes -&gt; (answer b and c) ☐ No -&gt; (skip to 19)</li> <li>b. If 'Yes', how was the naltrexone administered?</li> <li>☐ Oral ☐ Injectable</li> </ul>			
Methamphetamine	Heroin	Fentanyl	c. <i>If 'Yes'</i> , what was the last naltrexone dosage in the 60 days prior to episode completion?			
Other Opiates/ Opioids	Non-Prescription Methadone	PCP-Phencyclidine	(enter zero, if none and skip to 19)			
Other Hallucinogen	Other Amphetamine	Other Stimulant	18. For dosage level of Naltrexone greater than zero: Please describe the last naltrexone dosing:			
Benzodiazepine	Other Non-Benzodiazepine Tranquilizer	Barbiturate	<ul> <li>☐ Induction -&gt; (skip to 19)</li> <li>☐ Stabilization -&gt; (skip to 19)</li> <li>☐ Taper -&gt; (answer b)</li> <li>b. If 'Taper', is the naltrexone withdrawal voluntary or administrative?</li> </ul>			
Non-Barbiturate Sedative or	Inhalant	Over-the-Counter				
Hypnotic Oxycodone (OxyContin, Percocet, Percodan)	MDMA (Ecstasy)	Other Prescription Med	(mark only one)			
Spice	Dilantin	GHB/GBL	<ul> <li>In your own home/apartment</li> <li>In family or friend's home/apartment</li> </ul>			
Ketamine	Cannabinoids, Delta THC/Other Synthetic	Other Drug	<ul> <li>Therapeutic Community (TC)</li> <li>Public Facility/Institution</li> </ul>			
13. Did this consumer rece	ive or was expected to	receive methadone	Private Facility/Institution			
treatment? ☐ Yes -> (answer b) ☐ No	-> (skin to 15)		☐ Halfway House ☐ Group Home			
b. If 'Yes', what was the last	t methadone dosage in th	e 60 days	Residential Treatment Center			
prior to episode completion?			Correctional Facility			
mg `	zero, if none and skip to	·	CASAWORKS			
14. For dosage level of Met	hadone greater than ze	ro:				
Please describe the last me	thadone dosing:		☐ Other			
□ Induction -> (skip to 15) □ Stabilization -> (skip to 15)						
Taper $->$ (answer b)	/		<b>20. Referred Services:</b> (mark all that apply)			
b. <i>If 'Taper'</i> , is the methadone withdrawal voluntary or administrative?		SACOT				
		receive				
15. Did this consumer rece buprenorphine (mono or co	ombo products, such as		Community Support Team			
Suboxone, etc.) treatment?			Individual - SUD			
$\Box$ Yes -> (answer b and c)			□ Individual - MH			
b. If 'Yes', how was the bupr			Group - SUD			
. ,	Injection	the 60 days	Group - MH			
c. If 'Yes', what was the last prior to episode completion?	buprenorprime dosage in	the ou days	Psychiatric Services			
(enter	zero, if none and skip to .	17)	Medical Services			
16 For desage level of Bun	ronorphing greater tha	n zaroj	CASAWORKS			
16. For dosage level of Bup Please describe the last bu		11 2010.	AA/NA (Alcoholics Anonymous/Narcotics Anonymous)			
$\Box$ Induction -> (skip to 17)			Divid Based Outpatient Treatment			
$\Box$ Stabilization -> (skip to 17	)		DRA (Dual Recovery Anonymous)			
$\Box \text{ Taper } -> (answer b)$			□ NC Quitline			
b. <i>If 'Taper',</i> is the buprenc		ary or administrative?	Refused referral for services			

Confidentiality of SUD and MH consumer-identifying information is protected under Federal regulations 42 CFR Part 2 and the Health Insurance Portability and Accountability Act of 1996, P.L. 104-91 (HIPAA) or implementing regulations, 45 CFR Parts 160 and 164. Consumer-identifying information may be disclosed without the individual's consent to the Division of Mental Health, Developmental Disabilities, and Substance Use Services (DMH/DD/SUS) and to its authorized evaluation contractors under the audit or evaluation exception. Redisclosure of consumer-identifying information without the individual's consent is explicitly prohibited. Your questions may be directed to the NC-TOPPS ADATC Help Desk: nctoppsadatc@ncsu.edu. Sponsored by the NC MH/DD/SUS.

### **NC-TOPPS**

# **ADATC Episode Completion Interview**

-	
<b>**</b> Use this form for backup only. Enter data into web-	based system. (https://nctopps.ncdmh.net/adatc.htm)
If 'Consumer is Not Available/Already Been Discharged', skip questions 21-39. (END OF INTERVIEW)	24. Have you ever used medications, prescribed to you by a physician, in any manner and/or amount other than the
(for patients with length of stay **Use this form for backup only. Enter data into web- If 'Consumer is Not Available/Already Been Discharged',	<b>Part of the second series of the second second</b>
	<pre>     Yes -&gt; (answer c-1) □ No -&gt; (skip to 29)     c-1. If 'Yes', did you begin Nicotine Replacement Therapy     (NRT)? □ Yes -&gt; (skip to 29) □ No -&gt; (answer c-2)         c-2. If 'No', did you decline Nicotine Replacement         Therapy (NRT)?         □ Yes □ No </pre>

Confidentiality of SUD and MH consumer-identifying information is protected under Federal regulations 42 CFR Part 2 and the Health Insurance Portability and Accountability Act of 1996, P.L. 104-91 (HIPAA) or implementing regulations, 45 CFR Parts 160 and 164. Consumer-identifying information may be disclosed without the individual's consent to the Division of Mental Health, Developmental Disabilities, and Substance Use Services (DMH/DD/SUS) and to its authorized evaluation contractors under the audit or evaluation exception. Redisclosure of consumer-identifying information without the individual's consent is explicitly prohibited. Your questions may be directed to the NC-TOPPS ADATC Help Desk: nctoppsadatc@ncsu.edu. Sponsored by the NC MH/DD/SUS.

### **NC-TOPPS**

# **ADATC Episode Completion Interview**

(for patients with length of stay greater than or equal to 5 days)

\*\*Use this form for backup only. Enter data into web-based system. (https://nctopps.ncdmh.net/adatc.htm)

· · ·	
29. Since admission, has your family, guardian, or significant other been involved in any contact with staff concerning any of the following? (mark all that apply) ☐ Treatment services -> (answer b and c)	<b>33. During your treatment stay, did you try to hurt yourself or cause yourself pain on purpose (such as cut, burned, or bruised self)?</b>
Person-centered planning $->$ (answer b and c)	
$\Box \text{ None of the above } -> (skip to 30)$	34. During your treatment stay, did you have thoughts of suicide?
b. If 'Treatment services' or 'Person-centered planning', since	Yes No
admission, how often has your family, guardian, or significant	35. During your treatment stay, did you have thoughts of
other been involved in any contact with staff?	killing someone?
Once a week or more Twice a week or more	🗌 Yes 🔄 No
c. If 'Treatment services' or 'Person-centered planning', this	36. Females only: Have you ever been pregnant?
contact was mostly	$\Box$ Yes -> (answer 37 and 38)
Face-to-face	□ No -> (skip to 39)
By telephone	Unsure -> ( <i>skip to 39</i> )
🗖 Both	
<b>30.</b> If 'None of the above' is answered on question 29, <b>please</b>	37. Females only: Are you currently pregnant? Yes
specify a reason why no family, guardian, or significant	
other have been involved in person-centered planning or	
treatment services: (mark all that apply)	Unsure
Consumer has no family, guardian, or significant other	38. <u>Females only</u> : Have you given birth in the past year?
Consumer declines family involvement	$\Box$ Yes -> (answer b)
Family declines to be involved	□ No -> (skip to 39)
Scheduling conflicts	b. If 'Yes', how long ago did you give birth?
□ Other	Since admission
—	Less than 3 months ago
31. Have you ever experienced?	□ 3 to 6 months ago
$\Box Physical abuse -> (answer b)$	☐ 7 to 12 months ago
$\Box \text{Emotional/verbal abuse} \rightarrow (answer b)$	39. What are the possible barriers that may prevent you from
Sexual abuse $->$ (answer b) None of the above $->$ (skip to 33)	attending outpatient services? (mark all that apply)
b. If 'Physical abuse', 'Emotional/verbal abuse', and/or 'Sexual	□ No barriers to attending outpatient treatment
abuse', did you have an opportunity to discuss this issue during	Physical health problems
your treatment? ☐ Yes -> ( <i>skip to 33</i> )	$\Box$ Family or guardian issues (controlling spouse/partner, family illness, child/elder care, domestic violence, family cooperation)
<ul> <li>No -&gt; (answer c)</li> <li>c. If 'No', would you like to speak with a staff person about this issue before your discharge?</li> </ul>	Issues with treatment being offered (availability of appropriate services, type of treatment wanted by consumer not available, engagement issues, service locations, etc.)
□Yes □No	
32. Have you ever experienced childhood sexual abuse?	Stigma/Embarrassment
Yes -> (answer b)	Potential legal reasons (arrest, incarceration)
$\square$ No -> (skip to 33)	Transportation issues/Distance to provider
<ul> <li>b. If 'Yes', did you have an opportunity to discuss this issue during your treament?</li> <li>☐ Yes -&gt; (skip to 33)</li> </ul>	$\square$ Scheduling issues (potential work conflicts, appointment times not working with schedule)
	$\Box$ Lack of stable housing
No −> (answer c) c. If 'No', would you like to speak with a staff person about this issue before your discharge?	
Yes No	

#### Enter data into web-based system:

#### https://nctopps.ncdmh.net/adatc.htm

#### Do not mail this form

Confidentiality of SUD and MH consumer-identifying information is protected under Federal regulations 42 CFR Part 2 and the Health Insurance Portability and Accountability Act of 1996, P.L. 104-91 (HIPAA) or implementing regulations, 45 CFR Parts 160 and 164. Consumer-identifying information may be disclosed without the individual's consent to the Division of Mental Health, Developmental Disabilities, and Substance Use Services (DMH/DD/SUS) and to its authorized evaluation contractors under the audit or evaluation exception. Redisclosure of consumer-identifying information without the individual's consent is explicitly prohibited. Your questions may be directed to the NC-TOPPS ADATC Help Desk: nctoppsadatc@ncsu.edu. Sponsored by the NC MH/DD/SUS.

Attachment I:					
ICD-10-CM Diagnosis Codes					
Neurodevelopmental Disorders					
Learning Disorders (F81.0, F81.2, F81.81, F81.89)       Autism Spectrum Disorder (F84.0)					
Communication Disorders (F80.81, F80.89, F80.9)					
□ Intellectual Disabilities (F70, F71, F72, F73, F79, F88) □ Other Neurodevelopmental Disorders (F81.9, F88, F89)	1				
Motor and Tic Disorders (F82, F95.0, F95.1, F95.2, F95.9, F98.4)					
Substance-Related and Addictive Disorders					
Alcohol-Related Disorders (F10.10, F10.20)					
(Other) Drug-Related Disorders (F11.10, F11.20, F12.10, F12.20, F13.10,					
F13.20, F14.10, F14.20, F15.10, F15.20, F16.10, F16.20, F18.10, F19.20)					
Gambling Disorder (F63.0)					
Schizophrenia Spectrum and Other Psychotic Disorders					
Schizophrenia and Other Psychotic Disorders (F06.0, F06.1, F06.2, F20.81, F20.9, F22, F23, F25.9, F29)					
Bipolar and Related Disorders					
Bipolar I Disorder (F31.10, F31.11, F31.12, F31.13, F31.30, F31.31, F31.32, F31.4, F31.5, F31.73, F31.74, F31.75, F31.76, F31.9)					
Bipolar II Disorder (F31.81)					
Cyclothymic Disorder (F34.0)					
Depressive Disorders					
Major Depressive Disorder (F32.0, F32.1, F32.2, F32.3, F32.4, F32.5, F32.9, F33.0, F33.1, F33.2, F33.3, F33.41, F33.42, F33.9)					
Persistent Depressive Disorder (Dysthymia) (F34.1)					
Other Depressive Disorders (F32.9, F34.8, N94.3)					
Anxiety Disorders					
Anxiety Disorders (F40.02, F40.10, F40.218, F40.240, F40.241, F40.8, F41.0, F41.1, F41.8, F41.9, F91.2, F93	.0)				
Obsessive-Compulsive and Related Disorders					
Dbsessive-Compulsive and Other Related Disorders (F42, F45.21, F45.22, F63.3, F63.89, L98.1)					
Trauma- and Stressor-Related Disorders					
Posttraumatic Stress Disorder (PTSD) (F43.10, F43.12)					
Adjustment Disorders (F43.21, F43.22, F43.23, F43.24, F43.25)					
Other Trauma- and Stressor-Related Disorders (F43.0, F43.20, F43.8, F93.8, F94.1, F98.8)					
Dissociative Disorders					
Dissociative disorders (F44.0, F44.1, F44.81, F44.9, F48.1)					
Disruptive, Impulse-Control, and Conduct Disorders					
Conduct Disorder (F91.1, F91.2, F91.8) Impulse Control Disorders (F63.1, F63.2, F63.81)					
Oppositional Defiant Disorder (F91.3)					
Gender Dysphoria Disorders					
Gender Dysphoria Disorders (F64.1, F64.2)					
Neurocognitive Disorders					
Delirium Disorders (F05, F19.921, R40.0, R40.1)					
Major and Mild Neurocognitive Disorders (F01.50, F02.80, F02.81, G31.84, G31.9, R41.89)					
Personality Disorders					
Cluster A Personality Disorders (F21, F60.0, F60.1)	F60 7)				
Cluster B Personality Disorders (F60.2, F60.3, F60.4, F60.81)	100.7)				
Feeding and Eating Disorders					
$\square$ Anorexia Nervosa (F50.00) $\square$ Other Fooding and Fating Disorders (FE0.2, FE0.8, FE0.0, F08.21, F08.20, F08.2)					
Other Feeding and Eating Disorders (F50.2, F50.8, F50.9, F98.21, F98.29, F98.3)					
Other Disorders	3 That May Be				
Somatic Symptom and Related Disorders (F44.4, F45.1, F45.21, F45.22, F45.8, F45.9, F48.8, F54, F68.8)	al Attention				
Sevuel Dysfunction Disorders (E52.0, E52.1, E52.21, E52.31, E52.32, E52.4, E52.6, E52.8, P37)					
Sleep-Wake Disorders (F51.3, F51.8, G25.81, G4/.00, G4/.10, G4/.30, G4/.31, G4/.33, G4/.34, Conditions (any G47.35, G47.36, G47.411, G47.419, G47.52, G47.8, R06.3)	Loues not				
Paraphilic Disorders (F65.0, F65.1, F65.2, F65.3, F65.4, F65.51, F65.52, F65.81, F65.89, F65.9, F66) Version 02	//01/2025				